



**LucidQuest Intelligence**  
Accelerate your success

**SCIENTIFIC  
SESSIONS**

 **June 11 – 14**  
**CHICAGO, IL**

**2026**

# NLA 2026 Preview – Table of Contents

|                                                                                         |                              |
|-----------------------------------------------------------------------------------------|------------------------------|
| • <a href="#"><u>Emerging Trends in Lipid Management Strategy At NLA'26</u></a>         | <a href="#"><u>3-5</u></a>   |
| • <a href="#"><u>Key Sessions To Watch</u></a>                                          | <a href="#"><u>6-7</u></a>   |
| • <a href="#"><u>Industry-sponsored Sessions &amp; Focus Areas At NLA'26</u></a>        | <a href="#"><u>8-13</u></a>  |
| • <a href="#"><u>Competitive Landscape At a Glance at NLA'26</u></a>                    | <a href="#"><u>9</u></a>     |
| • <a href="#"><u>Key Industry-sponsored Sessions At NLA'26</u></a>                      | <a href="#"><u>10-12</u></a> |
| • <a href="#"><u>Emerging Assets &amp; Companies Receiving Visibility at NLA'26</u></a> | <a href="#"><u>13</u></a>    |
| • <a href="#"><u>What We're Watching For Post-congress</u></a>                          | <a href="#"><u>14</u></a>    |
| • <a href="#"><u>Get In Touch With LucidQuest</u></a>                                   | <a href="#"><u>15</u></a>    |



- **Lp(a) testing and risk assessment will remain a major focus area**

- Multiple scientific and educational sessions will focus on Lp(a) screening, cardiovascular risk assessment, and management strategies for patients with elevated Lp(a). The concentration of programming suggests continued efforts to integrate Lp(a) testing into routine cardiovascular prevention while clinicians await dedicated Lp(a)-lowering therapies



- **ApoC-III inhibition will continue to reshape management of severe hypertriglyceridemia and FCS**

- Sessions featuring Ionis' TRYNGOLZA and Arrowhead's plogasiran will highlight growing clinical experience with ApoC-III-targeted therapies. Discussions will focus on how these agents may influence treatment approaches in familial chylomicronemia syndrome and persistent chylomicronemia populations



- **Primary prevention is increasingly becoming a focus for intensive LDL-C lowering**

- Presentations discussing VESALIUS-CV, FOURIER, ODYSSEY Outcomes, and long-term PCSK9 inhibitor experience will reinforce interest in identifying patients who may benefit from earlier intervention before cardiovascular events occur



- **Genetic testing is moving closer to routine lipid care**

- Sessions on familial hypercholesterolemia screening, cascade testing, polygenic risk scores, and CRISPR-based approaches will emphasize the growing role of genetics in cardiovascular risk assessment and patient identification



- **Advanced imaging and digital risk assessment tools are gaining visibility in preventive cardiology**

- Sessions involving coronary plaque assessment, CCTA, polygenic risk scores, and imaging-guided prevention will explore how emerging technologies may improve cardiovascular risk stratification beyond traditional risk calculator



- **Rare lipid disorders will remain an important area of industry focus**

- Industry-sponsored programs from Regeneron, Chiesi, Alexion/AstraZeneca Rare Disease, Mirum, Ionis, and Arrowhead will focus on HoFH, LAL-D, FCS, and lipodystrophy. These sessions will continue to support earlier diagnosis and treatment optimization in historically under-recognized patient populations



# Key Sessions To Watch (1/2)

| Date         | Session Title (short)                                              | Type                    | Author / Institution | Why Watch                                                                           |
|--------------|--------------------------------------------------------------------|-------------------------|----------------------|-------------------------------------------------------------------------------------|
| 12 June 2026 | CRISPR: A One-Time Edit for a Lifetime of Control                  | Scientific Session      | Christie Ballantyne  | Will highlight how gene-editing approaches may reshape future lipid management      |
| 12 June 2026 | Primary Prevention: Are We Missing the Opportunity?                | Scientific Session      | Salim Virani         | Will frame evolving thinking around earlier lipid intervention                      |
| 13 June 2026 | VESALIUS-CV                                                        | Oral Scientific Session | Erin Bohula          | Will provide important context for LDL-C lowering in primary prevention populations |
| 13 June 2026 | Enlicitide Phase 3 CORALreef Lipids & HeFH                         | Scientific Session      | Christie Ballantyne  | Will provide one of the most notable updates for oral PCSK9 inhibition              |
| 13 June 2026 | Accelerating Lp(a) Testing in Community Health Centers             | Scientific Session      | Jeremy Skinner       | Will demonstrate practical approaches for expanding Lp(a) testing                   |
| 13 June 2026 | Early Detection of FH Through Point-of-Care Testing in 2-Year-Olds | Scientific Session      | Jose Lopez           | Could influence future FH screening strategies                                      |
| 13 June 2026 | Real-World Experience with ApoC-III Inhibition                     | Scientific Session      | Kamil Winnicki       | Will provide emerging real-world evidence for ApoC-III-targeted therapies           |
| 13 June 2026 | Lipid-Related Polygenic Risk Score and Coronary Calcium            | Scientific Session      | Tomoyo Hamana        | Will assess how genetic risk scores correlate with subclinical atherosclerosis      |



# Key Sessions To Watch (2/2)

| Date         | Session Title (short)                                               | Type               | Author / Institution | Why Watch                                                                         |
|--------------|---------------------------------------------------------------------|--------------------|----------------------|-----------------------------------------------------------------------------------|
| 14 June 2026 | Lipoprotein(a): The Genetic Inflammatory Fuel Driving Total CV Risk | Scientific Session | Anand Rohatgi        | Will provide insight into the evolving role of Lp(a) in cardiovascular prevention |
| 14 June 2026 | Non-Invasive Imaging in MASLD-Related Inflammation and Fibrosis     | Scientific Session | Kathleen Wyne        | Highlights the growing role of imaging-based risk assessment.                     |

# Industry-Sponsored Sessions & Focus Areas – NLA 2026





# NLA 2026– Competitive Landscape at a Glance

| Name                                      | Sessions | Companies / Assets                                  | Why It Matters                                                                                           |
|-------------------------------------------|----------|-----------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| ApoC-III inhibition in FCS and severe HTG | Multiple | Ionis / TRYNGOLZA;<br>Arrowhead / plozasiran        | ApoC-III inhibition is emerging as a major therapeutic approach in rare triglyceride disorders           |
| LDL-C lowering and primary prevention     | Multiple | Amgen / evolocumab;<br>Merck / enlicitide           | Discussions will focus on expanding intensive LDL-C lowering beyond secondary prevention                 |
| Lp(a) management and residual risk        | Multiple | Kaneka LIPOSORBER;<br>community testing initiatives | Increased focus on identifying and managing elevated Lp(a) ahead of dedicated therapies                  |
| Rare lipid disorders                      | Multiple | Regeneron, Chiesi,<br>Alexion, Mirum                | Industry efforts remain focused on improving diagnosis and treatment of underserved patient populations  |
| Genetics and precision prevention         | Multiple | Allelica; FH screening programs                     | Genetic testing and risk stratification are becoming increasingly integrated into lipid care             |
| Imaging-guided prevention                 | Multiple | Heartflow                                           | Imaging is being positioned as a tool to improve cardiovascular risk assessment and treatment decisions. |





# Key Industry-Sponsored Sessions at NLA 2026 (1/3)



- **Chiesi:**

- Focus Areas: HoFH and specialist lipid care
- The company will emphasize earlier identification and management of homozygous familial hypercholesterolemia while strengthening awareness of specialist treatment pathways



- **Heartflow:**

- Focus Areas: Imaging-guided prevention
- Heartflow will promote CCTA and plaque analysis as tools to personalize cardiovascular risk assessment and support earlier preventive intervention



- **Ionis:**

- Focus Areas: Severe hypertriglyceridemia and ApoC-III inhibition
- Through TRYNGOLZA-focused programming and severe hypertriglyceridemia education, Ionis will continue positioning ApoC-III inhibition as a foundational approach in triglyceride disorders



# Key Industry-Sponsored Sessions at NLA 2026 (2/3)



- **Kaneka LIPOSORBER:**

- Focus Areas: Elevated Lp(a) and residual risk
- The company presentations will highlight lipoprotein apheresis as a management strategy for patients with persistently elevated cardiovascular risk driven by Lp(a)



- **Allelica:**

- Focus Areas: Polygenic risk scores
- Allelica sessions will advocate for broader adoption of genetic risk assessment tools in preventive cardiology



- **Arrowhead:**

- Focus Areas: Familial chylomicronemia syndrome
- Session will reinforce the role of plozasiran in reducing triglycerides among patients with FCS





# Key Industry-Sponsored Sessions at NLA 2026 (3/3)



- **Regeneron:**

- Focus Areas: HoFH and EVKEEZA
- Regeneron will continue to support awareness of HoFH diagnosis and the role of ANGPTL3 inhibition in disease management



- **Alexion / AstraZeneca Rare Disease:**

- Focus Areas: LAL-D awareness
- Programming will focus on improving recognition of lysosomal acid lipase deficiency and reducing diagnostic delays



- **Amgen:**

- Focus Areas: Primary prevention and VESALIUS-CV
- Amgen will use VESALIUS-CV-related discussions to support broader consideration of intensive LDL-C lowering in high-risk patients without prior events

# Emerging Assets & Companies Receiving Visibility at NLA Education 2026



| Asset / Company        | 2026 Presence                                          |
|------------------------|--------------------------------------------------------|
| Enlicitide (Merck)     | Phase 3 CORALreef presentation                         |
| Plozasiran (Arrowhead) | FCS-focused educational session                        |
| TRYNGOLZA (Ionis)      | Severe hypertriglyceridemia programming                |
| Allelica               | Polygenic risk score and precision prevention sessions |
| Heartflow              | Plaque analysis and CCTA-focused sessions              |



# What We're Watching for Post-NLA 2026

- Whether VESALIUS-CV discussions strengthen support for intensive LDL-C lowering in primary prevention populations
- Whether enlicitide Phase 3 results improve the competitive positioning of oral PCSK9 inhibition versus established injectable PCSK9 therapies
- Whether emerging evidence for TRYNGOLZA and plogasiran further supports ApoC-III inhibition as a preferred approach in FCS and severe hypertriglyceridemia
- Whether Lp(a)-focused sessions, including testing initiatives and apheresis discussions, accelerate adoption of routine Lp(a) screening
- Whether polygenic risk scores and imaging-guided prevention tools demonstrate sufficient clinical utility to influence future lipid management strategies

# Strategic Insights and Strategy Development is our focus



COMPETITIVE STRATEGY  
AND INTELLIGENCE



DIGITAL HEALTH, ARTIFICIAL  
INTELLIGENCE AND IoE



GENE & CELL THERAPY



VACCINES & INFECTIOUS  
DISEASES



INVESTMENT INSIGHTS

e: [INFO@LQVENTURES.COM](mailto:INFO@LQVENTURES.COM)

w: [WWW.LQVENTURES.COM](http://WWW.LQVENTURES.COM)